Alkermes plc

Last updated
Alkermes plc
Company type Public
Industry Biotechnology
Founded1987;38 years ago (1987)
FounderMichael Wall
Headquarters
Dublin
,
Ireland [1]
Key people
Richard Pops (CEO)
RevenueIncrease2.svg US$1.1 billion (2022) [2]
Decrease2.svg US$-20.5 million
Decrease2.svg US$-158 million (2022)
Total assets Increase2.svg US$1.9 billion
Total equity Increase2.svg US$1 billion
Number of employees
2,100
Website www.alkermes.com

Alkermesplc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. [3] In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. [4] The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. [1]

Contents

Products

Alkermes has four proprietary commercial drug products [5] approved for the treatment of schizophrenia, bipolar I disorder, alcohol dependence and opioid dependence. These include olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination intended for the treatment of schizophrenia and bipolar I disorder; aripiprazole lauroxil (Aristada), a long-acting injectable for schizophrenia; and naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence.

Other products utilizing Alkermes' proprietary technologies include: diroximel fumarate (Vumerity) for multiple sclerosis, risperidone (microspheres) long-acting injectable (Risperdal Consta) for schizophrenia and bipolar I disorder, paliperidone palmitate (Invega Sustenna, Invega Trinza and Invega Hafyerain in the U.S., Xeplion, Trevicta and Bynnali in Europe) for schizophrenia. [6] [7]

In October 2023, Alkermes announced its first data related to its orexin 2 receptor (OXR2) agonist, alixorexton, previously known as ALKS 2680. Alixorexton is in development for the treatment of narcolepsy and idiopathic hypersomnia. [8]

In November 2023, Alkermes completed the planned separation of its oncology business into a new company, Mural Oncology, which plans to continue to work on the investigational interleukin-2 (IL-2) drug, nemvaleukin alfa. [9]

In May 2024, Alkermes completed the sale of its Athlone, Ireland facility to Novo Nordisk. [10]

In April 2025, Alkermes announced the initiation of a phase 2 study of alixorexton for the treatment of idiopathic hypersomnia. [11]

In July 2025, Alkermes announced positive topline results from Vibrance-1, a phase 2 study evaluating alixorexton for the treatment of narcolepsy type 1. [12]

In November 2025, Alkerms agreed to acquire sleep disorder drugmaker Avadel Pharmaceuticals for up to $2.37 billion, which includes $21 per share in cash plus $1.50 per share contingent on expanded approval of Lumryz by the end of 2028. This resulted after a bidding war between Alkermes and Danish pharmaceutical company Lundbeck. Alkermes had originally offered up to $2.1 billion, which inlcuded $18.50 per share plus the contingent $1.50. The deal is expected to close in the first quarter of 2026. [13]

References

  1. 1 2 Robert Weisman (10 May 2011). "Alkermes to buy Irish drug maker". Boston Globe.
  2. ↑ "Alkermes PLC".
  3. ↑ "Alkermes And Richard Pops — The Evolution Of A Company And Its Leader". LifeScienceLeader.com. 1 May 2019. Retrieved 21 June 2019.
  4. ↑ "Alkermes Reels In Elan's Drug Technology Business". Forbes.com. 9 May 2011. Retrieved 13 October 2011.
  5. ↑ "Alkermes, Inc. Company Information". Drugs.com. Retrieved 2023-11-22.
  6. ↑ "U.S. Third-Party Medicines | Alkermes". www.alkermes.com. Retrieved 2023-11-22.
  7. ↑ "Alkermes EU Pharmaceutical Manufacturing Products | Alkermes". www.alkermes.com. Retrieved 2023-11-22.
  8. ↑ "Orexin Receptor ALKS 2680 Demonstrates Positive Phase 1 Findings". Neurology live. 2023-11-06. Retrieved 2023-11-22.
  9. ↑ "Alkermes separates cancer drug business as new company Mural". BioPharma Dive. Retrieved 2023-11-22.
  10. ↑ "Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk". alkermes.com. 2024-05-02. Retrieved 2024-06-24.
  11. ↑ "Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia". Alkermes plc. April 1, 2025. Retrieved April 15, 2025.
  12. ↑ "Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1a". Alkermes plc. July 21, 2025. Retrieved July 30, 2025.
  13. ↑ Choudhury, Kamal; Mahatole, Siddhi (November 19, 2025). "Avadel board backs Alkermes' higher offer over Lundbeck proposal". Rueters . Retrieved December 4, 2025.{{cite web}}: CS1 maint: url-status (link)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.